TirzepatideGIP/GLP-1 PeptideSafety Rating 8/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Save ~98% vs Zepbound LillyDirect (single-dose vials)
Research-grade Tirzepatide is for laboratory and research use only, not approved for human consumption. Always consult a licensed physician before working with any compound. FDA-approved 2022 (Mounjaro) and 2023 (Zepbound). Eli Lilly's direct-to-consumer vial program brought cash-pay floor to $349 for 2.5mg starter doses.
See all Tirzepatide vendors →Price Comparison
Compare vendors · per 5mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| Puratek PeptidesBest $/mgCOA ✓ · 3P | $80.95 | $1.35 | May 19, 2026 | Buy → |
| Red River PeptidesCOA ✓ · 3P | $93.50 | $1.56 | May 19, 2026 | Buy → |
| Puratek PeptidesCOA ✓ · 3P | $53.96 | $1.80 | May 19, 2026 | Buy → |
| Red River PeptidesCOA ✓ · 3P | $72.25 | $1.81 | May 19, 2026 | Buy → |
| Red River PeptidesCOA ✓ · 3P | $56.95 | $1.90 | May 19, 2026 | Buy → |
Overview
About Tirzepatide
Mechanism of action
Dual GIP and GLP-1 receptor agonist. Enhances insulin secretion, reduces glucagon, suppresses appetite, slows gastric emptying, improves insulin sensitivity.
Safety profile
Nausea, vomiting, diarrhea, decreased appetite, constipation, pancreatitis risk, gallbladder issues, thyroid tumor risk (theoretical). · Extensive Phase III data; GI side effects manageable; thyroid warning animal-only; strong efficacy
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Tirzepatide below your target.
Safety & Interactions
Contraindications & Drug Interactions
Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.
Personal or family history of medullary thyroid carcinoma (MTC). FDA black-box warning.
MEN 2 syndrome.
Prior serious hypersensitivity reaction.
Related pages
More on Tirzepatide
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- SURMOUNT-1 (NEJM 2022, n=2,539) established tirzepatide as the most efficacious approved obesity pharmacotherapy at the time — the 15 mg dose achieved a mean 22.5% body weight reduction vs 2.4% with placebo over 72 weeks, with 57% of participants achieving ≥20% weight loss.
- SURMOUNT-2 (Lancet 2023) confirmed tirzepatide's efficacy in adults with both obesity and T2D, with the 15 mg dose achieving -14.7% weight change vs -3.2% with placebo — and improvements in HbA1c, blood pressure, and lipids, demonstrating metabolic benefits beyond weight loss alone.